![]() | This article's lead section may be too long.(March 2024) |
Industry | Pharmaceuticals |
---|---|
Headquarters | , United States |
Key people | Peter Friedli (Chairman) Greg Law (CFO) Frank Czworka (COO) Alla Danilkovitch (CSO) James Burns (Co-Founder) Dr. Arnold Caplan (Co-Founder) Kevin Kimberlin (Co-Founder) |
Products | Grafix, Stavik, Cartiform, BIO4, Osteocel, Prochymal |
Website | www![]() |
Osiris Therapeutics, Inc. was founded in March 1993 following the identification of mesenchymal stem cells (MSCs) by Dr. Arnold Caplan and colleagues at Case Western Reserve University in Cleveland Ohio. [1] Dr. Caplan contributed a license to certain technology and joined Kevin Kimberlin, James S. Burns, a biotech venture capitalist, and Peter Friedli, as lead investor, to launch Osiris, named after the Egyptian god of fertility, resurrection, and the afterlife. [2] Early financing was provided by a number of entities, including Three Arch Bay Health Sciences Fund and Spencer Trask & Co. [1] By 1994, the state of Maryland provided a loan and equity investment to lure the company from Ohio in 1995.
A peer company, StemCells, emerged in 1995 in California with a focus on neural regeneration, but using stem cell technology emerging from the laboratory of Irving Weissman at Stanford University. [3]
The year 1997 saw the start of a multi-million dollar research and licensing arrangement with Novartis, which initially acquired 8% of the company. It dedicated 65 employees to develop stem cell treatments for bone and cartilage disorders, including underwriting the cost of clinical trials, an arrangement that lasted until at least 1999. [1] [4] At the time, osteoporosis and arthritis were the top targets of Novartis research. [1] The only direct competitor of Osiris at the time was a unit of Novartis, Systemix, which focused on stem cell treatments for cancer. Systemix was outside the scope of the deal Osiris had struck with Novartis. [1] At the time, Osiris held also a majority stake in Gryphon, a blood stem cell technology exploitation firm spun out of Johns Hopkins Medical School. [1]
The company's first chief executive officer (CEO) was co-founder James Burns, who held the position from the company's inception through at least 1999. [1] [4] The company's Chief Financial Officer around this time was Michael Demchuk Jr. [1]
In 2006, when the company had 84 employees, Jeffries and Lazard Capital market took Osiris public, on NASDAQ, offering up 13% of the company as shares and raising $38.5 million, with funds intended for research, product development, loan servicing and clinical trial expenses. C. Randall Mills was CEO. At the time of the IPO, Osiris was considered to be "the closest in (the United States) to bring a pure stem cell product to the market", with a marketed drug for bone regeneration called Osteocel. The company sold Osteocel to NuVasive in 2009 for an upfront payment of $35 million at closing, and an additional $50 million in milestone payments. [5]
In 2010, Osiris received the first regulatory clearance in the world for a systemically administered stem cell drug, [6] called Prochymal or remestemcel-L. [7] IIt was approved for pediatric Graft-versus-Host Disease (GvHD). In 2013, Osiris sold its MSC drug and associated patents to Mesoblast of Australia and the drug was renamed Ryoncil. [8] Osiris had spent more than two decades working on this product and the proceeds from this sale allowed the company to focus on a line of wound-healing projects. [9]
Osiris transitioned from product research to commercialization with the introduction of Osteocel, Graphix, Stravix, and Chondrogen. In 2016, CEO, Lode Debrabandere, resigned. He was succeeded by the company's chief business officer, Dwayne Montgomery, then David and then Linda Palczuk, formerly of AstraZeneca. In March 2017, shares of Osiris were temporarily delisted from the NASDAQ stock exchange as the company failed to meet the exchange's requirements, including failure to file an annual report, [10] after being granted additional time for compliance. [11] The company was relisted on the NASDAQ in August 2018. [12] [13]
In 2019, Osiris was acquired for $660 million by Smith & Nephew plc, a global medical technology business. [14] [15] The company had $142 million in revenues for 2018 and 360 employees, all of whom were expected to remain with the firm, which would operate as a subsidiary to its parent. [15]
Ryoncil was tested in a March 2020 pilot study at Mount Sinai Hospital in New York City on late-stage, ventilator-assisted Covid-19 patients suffering Acute Respiratory Distress Syndrome. [16] Based on the results, the FDA approved a Phase 2/3 study on 300 patients at 30 sites around the U.S. The Cardiothoracic Surgical Trials Network, funded by the National Institutes of Health, and Mesoblast (the owner of the product) commenced that trial on May 5, 2020. [17]
Affiliation of all authors was with Osiris unless otherwise noted.
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
Astellas Institute for Regenerative Medicine is a subsidiary of Astellas Pharma located in Marlborough, Massachusetts, US, developing stem cell therapies with a focus on diseases that cause blindness. It was formed in 1994 as a company named Advanced Cell Technology, Incorporated (ACT), which was renamed to Ocata Therapeutics in November 2014. In February 2016 Ocata was acquired by Astellas for $379 million USD.
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
Christoph Westphal is an American biomedical businessman.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.
The Ohio bioscience sector strength was ranked #4 among USA states in 2008 by Business Facilities magazine.
United Therapeutics Corporation is an American publicly traded biotechnology company and public benefit corporation listed on the NASDAQ under the symbol UTHR. It develops novel, life-extending technologies for patients in the areas of lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
Prochymal is a stem cell therapy made by Osiris Therapeutics. It is the first stem cell therapy approved by Canada. It is also the first therapy approved by Canada for acute graft-vs-host disease (GvHD). Also known as remestemcel-L, Prochymal was sold to Australia-based Mesoblast in 2013 at which time its brand name was changed to Ryoncil.
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
United States of America v. Regenerative Sciences, LLC, 741 F.3d 1314, was a decision in the United States Court of Appeals for the District of Columbia Circuit filed on February 4, 2014 concerning more than minimally manipulated cell therapies and whether they are considered part of medical practice or a drug, the latter subjecting it to regulation under the Food and Drug Administration (FDA). Regenerative Sciences LLC marketed a therapy procedure called Regenexx-C for the treatment of arthritis and orthopedic injury that involved extraction and culture of mesenchymal stem cells from the same patient which were later reinjected. In 2008, The FDA notified Regenerative Sciences LLC that the procedure may not be in compliance with their regulation using an Untitled Letter, which began a series of suits and counter suits, leading to the 2014 decision upholding the FDA’s regulation of more than minimally manipulated stem cell therapies.
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Gregory L. Verdine is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
Mustang Bio is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency (X-SCID).
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.